A Donanemab Prevention Study in Participants with Alzheimer’s Disease
Disease/Condition: Alzheimer’s disease
Enrollment Opens: 01-01-2022
Enrollment Closes: TBD
This is a preventative trial for those at risk for Alzheimer’s disease. The investigational product is an anti-amyloid antibody aimed at removing the amyloid plaques associated with Alzheimer’s disease. This study is also called the Trailblazer 3 Trial, and is sponsored by Eli Lilly and Company.
Study ID: I5T-MC-AACM
To Enroll: Call 503-476-9788 or schedule your free over-the-phone memory screen here: https://www.centerforcognitivehealth.com/resources/free-memory-screens/
Posted by: Center for Cognitive Health | https://www.centerforcognitivehealth.com/clinicaltrials/